Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2464-2469

  Shibakita, Muneaki ^a   Tachibana, Mitsuo ^a   Dhar, Dipok K ^a   Kotoh, Tsukasa ^a   Kinugasa, Shoichi ^a   Kubota, Hirofumi ^a   Masunaga, Reiko ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD8; ANTIGENS, CD95; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032836476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
2. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
3. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
4. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95(APO-1/Fas)ligand- expressing tumor cells - a mechanism of immune evasion? Nat. Med., 2: 1361-1366, 1996.
5. Yano, H., Fukuda, K., Haramaki, M., Momosaki, S., Ogasawara, S., Higaki, K., and Kojiro, M. Expressing of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. J. Hepatol., 25: 454-464, 1996.
6. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinoma express Fas ligand. Cancer Res, 57: 1007-1012, 1997.
7. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Meir, E. G. V., Tribolet, N., Tschopp, J., and Dietriche, P. Y. Fas ligand expressing by astrocytoma in vivo: maintaining immune privilege in the brain. J. Clin. Invest., 99: 1173-1178, 1997.
8. Rabinowich, H., Reichert, T., Kashii, Y., Gastman, B. R., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J. Clin. Invest., 101: 2579-2588, 1998.
9. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas ligand in liver metastasis of human colonic adenocarcinoma. Proc. Natl. Acad. Sci. USA, 94: 6420-6425, 1997.
10. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., and Ohgaki, H. Up-regulation of Fas(APO/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res, 58: 2057-2062, 1998.
11. Rosenberg, S. A. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med., 47: 481-491, 1996.
12. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC). 267: 1449-1456, 1995.
13. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brandy, C., Roche, D., Collins, J. K., and Shanahan, F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 160: 5669-5675, 1998.
14. International Union Against Cancer staff. TNM classification of malignant tumors, Ed. 5. New York: Willy-Liss, 1997.
15. Tachibana, M., Kinugasa, S., Dhar, D. K., Tabara, H., Masunaga, R., Kotoh, T., Kubota, H., and Nagasue, N. Prognostic factors in T1 and T2 squamous cell carcinoma of the thoracic esophagus. Arch. Surg., 134: 50-54, 1999.
16. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn. J. Surg., 11: 127-139. 1981.
17. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Dukes, R. C. A role for CD95 ligand in preventing graft rejection. Nature (Lond.), 377: 630-632, 1995.
18. Busch, C., Malmstrom, P. U., Norlen, B. J., Sallstrom, J., Brodin, T., and Lundblad, A. A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. Anticancer Res., 8: 81-88, 1988.
19. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res, 58: 3491-3494, 1998.
20. Kaplan, E. L., and Meier, P. Nonparametric estimation for incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
21. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. Ser. B., 34: 187-220, 1972.
22. Tachibana, M., Tabara. H., Kotoh, T., Kinugasa, S., Dhar, D. K., Hishikawa, Y., Masunaga, R., Kubota, H., and Nagasue, N. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am. J. Gastroenterol., 94: 757-765, 1999.
23. Daly, J. M., Karnell L. H., and Menck, H. R. National cancer data base report on esophageal carcinoma. Cancer (Phila.), 78: 1820-1828, 1996.
24. Iizuka, T., Isono, K., Kakegawa, T., and Watanabe, H. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Chest, 96: 1005-1011, 1989.
25. Ohbu, M., Saegusa, M., and Okayasu, I. Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Virchows Arch., 427: 271-276, 1995.
26. Ademmer, K., Ebert, M., Muller-Ostermeyer, F., Friess, H., Buchler, M. W., Schubert, W., and Malferthemer, P. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+ CD18+ cells and CD8+ CD103+ cells by multi-epitope imaging. Clin. Exp. Immunol., 112: 21-26, 1998.
27. Glass, A., Walsh, C. M., Lynch, D. H., and Clark, W. R. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol., 156: 3638-3644, 1996.
28. Hahne, M., Peitsch, M. C., Irmler, M., Schroter, M., Lowin, B., Rousseau, M., Bron, C., Renno, T., French, L., and Tschopp, J. Characterization of non-functional Fas ligand of gld mice. Int. Immunol., 7: 1381-1386, 1995.
29. Freeman, M. R. Schneck, F. X., Gagnon, M. L., Corless, C, Soker, S., Niknejad, K., Peoples G. E., and Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res., 15: 4140-4145, 1995.